Importance The primary analysis of the SELECT randomized clinical trial suggests that semaglutide reduced the rates of cardiovascular (CV) death, myocardial infarction, and stroke in patients with established CV disease (CVD) and overweight or obesity without diabetes. However, the effect of semaglutide on hospitalizations in this population remains unknown. Objective To determine the impact of semaglutide on total hospital admissions and duration of hospital stay. Design, Setting, and Participants The SELECT trial included patients aged 45 years or older with established CVD and a body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) of 27 or higher without diabetes at 804 clinical settings across North America, South America, Europe, Asia, Africa, and Australia. Patients were randomized from October 2018 to March 2021. This prespecified exploratory analysis was conducted from February 2024 to September 2025. Interventions Once-weekly subcutaneous semaglutide, 2.4 mg, or placebo. Main Outcomes and Measures The total number of hospital admissions and days in hospital between the semaglutide and placebo groups. Results A total of 17 604 patients (median [IQR] age, 61.0 [55.0-68.0] years; 4872 female patients [27.7%]; median [IQR] BMI, 32.1 [29.7-35.7]) were followed up for a median (IQR) period of 41.8 (33.0-47.0) months. There were 11 287 hospital admissions. The number of total hospitalizations was lower in the semaglutide group vs placebo for any indication (18.3 vs 20.4 admissions per 100 patient-years; mean ratio [MR], 0.90; 95% CI, 0.85-0.95; P < .001) and for serious adverse events (15.2 vs 17.1 admissions per 100 patient-years; MR, 0.89; 95% CI, 0.84-0.94; P < .001). The number of days hospitalized for any indication per 100 patient-years was lower in the semaglutide group vs placebo (157.2 vs 176.2 days; rate ratio [RR], 0.89; 95% CI, 0.82-0.98; P = .01), as well as hospitalizations for serious adverse events (137.6 vs 153.9 days; RR, 0.89; 95% CI, 0.81-0.98; P = .02). No heterogeneity was observed for the reduction of hospital admissions with semaglutide in selected subgroups, including BMI, age, and sex. Conclusions and Relevance In this prespecified exploratory analysis of the SELECT randomized clinical trial, the trial cohort had a high rate of hospital admissions. Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, extending its benefits beyond CV risk reduction.

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease / S.J. Nicholls, D.H. Ryan, J. Deanfield, D. Ferreira, C.C. Lang, A. Michael Lincoff, I. Lingvay, C. Lübker, P. Pérez Terns, S. Rasmussen, S. Stensen, P.E. Weeke, S.E. Kahn, D.E. Nibouche, M. Chettibi, N. Hammoudi, A. Porto, A. Oviedo, H.D. Sanabria, M. Casas, E. Farias, E. Duronto, C. Chacon, A. Villarino, J.M. Farias, C.J. Zaidman, C. Morbey, D.M. Colquhoun, E.I. Ekinci, M. Leung, M. William, K. Kostner, M. Shirazi, D. Cross, J. Amerena, P. Purnell, M. Arstall, W.P. Abhayaratna, H. Toplak, R. Prager, B. Ludvik, A. Kautzky-Willer, U. Hanusch, E. Aigner, S. Kaser, M. De Pauw, P. Vanduynhoven, P. Van De Borne, C. Vercammen, J. Verwerft, M. Vrolix, L.A. Turatti, J.F. Saraiva, C. Cercato, A.P. Kormann, S.O. Leite, P. Rossi, F.B. Arantes, L.N. Maia, S.E. Kaiser, A.G. Fonseca, H.R. Kurtz Lisboa, D.R. Franco, J.C. Nicolau, P.S. Farsky, L.E. Ritt, A. Goudev, D. Vassilev, N. Runev, B. Georgiev, T. Katova, I. Petrov, V. Gelev, M. Milanova, A. Postadzhiyan, M. Tokmakova, Y. Yotov, S. Tisheva Gospodinova, D.A. Minkova, Z.R. Prakova-Teneva, S.P. Vasileva, A. Egan, G.M. Tsoukas, S. Verma, R. Bourgeois, P. Filteau, R. Vijayaraghavan, M. Hartleib, T. Spaic, J. Stewart, A.S. Pandey, R. Rabasa-Lhoret, F. St-Maurice, J.Y. Cha, S. Pedersen, R. Allison, P. Poirier, M. Langlois, D. Lau, Y. Robitaille, J. Weisnagel, C. Constance, S. Datta, N. Garg, T. Salter, N. Vale, G. Vallieres, K. Peters, G. Tellier, R. Botero Lopez, M.A. Urina Triana, A.J. Cadena Bonfanti, J.L. Accini Mendoza, J.A. Rodriguez Plazas, C.A. Martinez Cano, D. Milicic, S. Canecki Varzic, H. Budincevic, D. Delic-Brkljacic, A. Ruzic, I. Kruljac, K. Fuckar, A. Linhart, J. Malecha, O. Cermak, P. Koleckar, Z. Klimsa, L. Kuchar, E. Malicherova, J. Stasek, M. Haluzik, A. Vesela, M. Mæng, J.D. Hove, K. Egstrup, S.E. Jensen, G. Gislason, M. Bøttcher, M. Pietilä, E. Ilveskoski, T. Lakka, P. Ahtiainen, O. Ukkola, L. Niskanen, T. Keski-Opas, F. Schiele, D. Stephan, C. Petit, M. Kerneis, B. Cariou, G. Steg, B. Verges, J. Hulot, T. Demicheli, J. Thuan, G. Barone Rochette, B. Gatta-Cherifi, P. Serusclat, A. Al-Zoebi, K. Appel, K. Kreutzmann, J. Chevts, R.J. Denger, H. Eggebrecht, C. Von Engelhardt, A. Hagenow, P. Heymer, S. Jacob, W. Jungmair, G. Kahrmann, H. Kempe, C. Von Münchhausen, M. Lehrke, J. Wagner, M. Froer, J. Sauter, S. Meyhöfer, H. Zeller, A. Segner, H. Stahl, J. Steindorf, K. Sturm, T. Schaum, U. Wendisch, E. Liberopoulos, A. Bargiota, K. Tziomalos, V. Lambadiari, E. Pagkalos, A. Kokkinos, G. Argyrakopoulou, G. Siasos, S. Patsilinakos, L. Lanaras, A. Kartalis, G. Ntaios, K. Stamatelopoulos, E. Tsougos, D. Páll, G. Kocsis, R. Takács, M. Baranyai, G. Lupkovics, A. Piros, L. Könyves, U. Kaul, S. Mittal, J. Pal Singh Sawhney, S. Garg, A. Roy, D. Gandotra, N. Thomas, D. Kahali, R.K. Abhaichand, J. Christopher, S. Hiremath, J. Kannan, R. Sethi, M.K. Shah, A. Naik, G. Prafulla Kerkar, K. Varghese, A. Abhyankar, A. Bhagwat, G.S. Wander, A.K. Chopra, K.M. Parvathareddy, S. Bansal, A.U. Mahajan, R.B. Pothineni, D. Desai, V. Vijan, D.K. Agarwal, M. Fulwani, J. Arneja, P. Desai, V. Maher, D. Molony, K. Mcdonald, M. Byrne, D. O'Shea, S. Sreenan, C. Le Roux, O. Mosenzon, R. Durst, A. Bashkin, Y. Sofer, V. Vishlitzky, G. Segal Lieberman, M. Shechter, D. Dicker, T. Zornitzki, I. Liberty, N. Shehadeh, Y. Arbel, S. Buscemi, U. Pagotto, R. Vettor, F. Santini, G. Mingrone, F. Dotta, F. Cortinovis, G. Cogni, S. Bo, L. Frittitta, A. Malavazos, M. Bucci, E. Mannucci, P. Sbraccia, A.M. Colao, M.C. Zatelli, F. Muratori, F. Leonetti, D. Tuccinardi, M. Mirani, C. Berra, M. Ohsugi, H. Tanaka, H. Onaka, A. Watanabe, T. Sugiura, K. Morisaki, T. Nagano, M. Doi, M. Natsuaki, N. Miyamoto, K. Fujii, F. Oh, S. Mitomo, M. Kawanishi, R. Kitamura, H. Maeda, T. Miyake, N. Kinoshita, A. Sato, Y. Takeuchi, O. Ueda, A. Kiyosue, S. Kodera, M. Manita, Y. Fukushima, M. Kinoshita, M. Yamasaki, A. Sueyoshi, T. Ando, K. Hanaoka, T. Isawa, Y. Hata, H. Kunishige, M. Oguri, M. Abe, T. Matsumoto, Y. Ono, Y. Okada, T. Kato, T. Koga, R. Fujita, T. Sakamoto, H. Okayama, T. Kadokami, H. Yamaguchi, T. Iwasawa, I. Maeda, H. Teragawa, H. Ezaki, A. Lace, I. Veze, I. Rezgale, G. Latkovskis, I. Sime, D. Teterovska, G. Rancane, I. Klavina, L.H. Bang, T.K. Ong, S. Krishinan, L.Y. Lee, N. Ali, A.I. Ruhani, Z. Hussein, A. Rosman, I.B. Abidin, W.M. Wan Mohamed, S.S. Kasim, E.C. Morales Villegas, R. García Reza, J.L. Arenas León, J.R. Lazcano Soto, A.E. Bazzoni Ruiz, P.A. Garcia Hernandez, S.A. Jimenez-Ramos, M.A. Arias Mendoza, M.O. De Los Rios Ibarra, A.P. Van Beek, J. Schaap, H. Swart, F.M.A.C. Martens, P. Nierop, T. Vossenberg, C. Van Der Zwaan, R. Dorman, B. Groenemeijer, T.J. Römer, J. Hjelmesaeth, S. Tonstad, S. Halvorsen, L. Gullestad, T. Gretland Valderhaug, H.O. Høivik, R.G. Høgalmen, O.K. Nygård, E. Rice, P. Bogdanski, E. Franek, G. Gajos, L. Ostrowska, E. Szyprowska, M. Lukaszewicz, G. Kania, G. Skoczylas, M. Kujawiak, I. Wozniak, W. Chrustowski, M. Jozefowska, A. Leksycka, J. Jurowiecki, W. Czochra, G. Pulka, A. Karczmarczyk, B. Stogowska-Nikiciuk, P. Kalmucki, M. Beckowski, S. França, L. Fonseca, C. Martins, P. Monteiro, F. Pinto, N. Hancu, A. Vlad, L. Pop, A. Onaca, A. Cif, M. Kurtinecz, I.M. Vladu, C. Constantin, V. Nafornita, C. Toarba, S. Constantinescu, R. Avram, G. Nicolescu, B. Popa, D. Cosma, L. Marin, D.V. Reurean Pintilei, M. Morosanu, N.M. Mîndrescu, C.V. Mistodie, C.V. Badiu, S. Lupu, D. Enculescu, E. Caceaune, G. Enache, I.G. Gordeev, O. Shaydyuk, Z. Kobalava, T. Khlevchuk, M. Ezhov, V. Mareev, O. Vorobyeva, T. Markova, P. Ermakova, O.O. Bolshakova, D. Alpenidze, K. Zrazhevskiy, R. Sardinov, A. Obrezan, A. Zalevskaya, O. Zagrebelnaya, I.V. Dvoryashina, D. Platonov, L. Khaisheva, E. Shutemova, M.Y. Sergeeva Kondrachenko, O. Smolenskaya, L.A. Suplotova, S. Shalaev, O. Gilinskaya, O. Barbarash, V.V. Ryabov, A.A. Boshchenko, Y. Samoilova, N.G. Veselovskaya, T.A. Lysenko, E.A. Zhdanova, M. Zykov, L. Belousova, A.B. Peskov, I. Ipatko, I. Gurieva, D. Ruyatkin, E. Antonova, E.E. Kazakova, O. Ershova, O. Vinogradova, G.N. Guseva, Y. Pergaeva, M. Kharakhulakh, M. Sorokin, I. Krivosheeva, A. Galyavich, T. Sveklina, N. Lalic, K. Lalic, N. Djenic, M. Vukicevic, E. Stokic, M. Asanin, G. Stankovic, A. Ristic, I.O. Ebrahim, D. Urbach, C. Corbett, L. Lombard, A. Badat, M. Fulat, C. Kapp, V.N. Bandezi, N. Moosa, D.M. De Jong, N. Tsabedze, E. Van Der Walt, E. Van Nieuwenhuizen, S. Wadvalla, L. Burgess, K. Coetzee, S.Y. Dawood, J. Peter, L. Van Zyl, N. Fourie, J.J. Lombaard, E.M. Makotoko, P. Jugnundan, Z.E. Punt, E. Klug, F. Tinahones, C. De Pablo, C. De La Cuesta, A. Soto González, J.F. Merino Torres, L. Masmiquel Comas, M. Rivas Fernández, A. Castro, C. Morales Portillo, P. Mezquita Raya, O. González Albarrán, L. Rydén, B. Eliasson, H. Holmer, T. Mooe, K. Eliasson, C. Lindholm, C. Wu, I. Hsieh, H. Yeh, M. Liu, T. Lee, S. Suwanwalaikorn, A. Suwanagool, D. Piyayotai, S. Buranapin, P. Vathesatogkit, C. Udommongkol, N. Sansanayudh, S. Kiatchoosakun, W. Wongcharoen, S. Dagdelen, Y.A. Sonmez, S. Sancak, M. Kayikcioglu, M. Unubol, R. Sari, O.S. Bakiner, A. Celik, Y. Altuntas, D. Gogas Yavuz, E. Ozpelit, I. Gul, O. Ozdogan, D. Yazici, M. Araz, M. Adas, M.M. Tuna, O. Soyluk Selcukbiricik, M. Kanadasi, A. Oguzhan, O. Parkhomenko, Z. Lysak, L. Rudenko, V. Velychko, O. Levchenko, Y. Mostovoy, M. Stanislavchuk, M. Kushnir, I. Vyshnyvetskyy, T. Ilashchuk, O. Buriakovska, V. Leonidova, Y. Kyyak, O. Horoshko, L. Todoriuk, G. Myshanych, J. Wilding, R. Andrews, N. Asamoah, M. Barber, S. Bellary, A. Broadley, M. Capehorn, R. Clark, P. Clifford, J. Stoker, S. Creely, C. Dang, S. Dobson, P. English, E. Jackson-Voyzey, D. Tatovic, P. Keeling, J. Khoo, M. Lynch, K. Lee, B. Mcgowan, Y. Beerachee, A. Miras, M. Myint, S. Nair, N. Paul, H. Price, H. Randeva, T. Sathyapalan, R. Senior, R. Sharma, S. Sharma, A. Strzelecka, N. Swanson, G. Tait, B. Vaidya, R. Vincent, J. Wakeling, P. Wilson, Y. Wong, N. Wyatt, J.M. Agaiby, A. Al-Karadsheh, C. Apovian, A.A. Arif, V.R. Aroda, H.C. Shea, O. Barnum, M. Berk, I. Pereira, W.C. Biggs, L. Billings, D. Brautigam, A.P. Brockmyre, M.J. Budoff. - In: JAMA CARDIOLOGY. - ISSN 2380-6583. - (2025). [Epub ahead of print] [10.1001/jamacardio.2025.4824]

Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease

A. Malavazos;
2025

Abstract

Importance The primary analysis of the SELECT randomized clinical trial suggests that semaglutide reduced the rates of cardiovascular (CV) death, myocardial infarction, and stroke in patients with established CV disease (CVD) and overweight or obesity without diabetes. However, the effect of semaglutide on hospitalizations in this population remains unknown. Objective To determine the impact of semaglutide on total hospital admissions and duration of hospital stay. Design, Setting, and Participants The SELECT trial included patients aged 45 years or older with established CVD and a body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) of 27 or higher without diabetes at 804 clinical settings across North America, South America, Europe, Asia, Africa, and Australia. Patients were randomized from October 2018 to March 2021. This prespecified exploratory analysis was conducted from February 2024 to September 2025. Interventions Once-weekly subcutaneous semaglutide, 2.4 mg, or placebo. Main Outcomes and Measures The total number of hospital admissions and days in hospital between the semaglutide and placebo groups. Results A total of 17 604 patients (median [IQR] age, 61.0 [55.0-68.0] years; 4872 female patients [27.7%]; median [IQR] BMI, 32.1 [29.7-35.7]) were followed up for a median (IQR) period of 41.8 (33.0-47.0) months. There were 11 287 hospital admissions. The number of total hospitalizations was lower in the semaglutide group vs placebo for any indication (18.3 vs 20.4 admissions per 100 patient-years; mean ratio [MR], 0.90; 95% CI, 0.85-0.95; P < .001) and for serious adverse events (15.2 vs 17.1 admissions per 100 patient-years; MR, 0.89; 95% CI, 0.84-0.94; P < .001). The number of days hospitalized for any indication per 100 patient-years was lower in the semaglutide group vs placebo (157.2 vs 176.2 days; rate ratio [RR], 0.89; 95% CI, 0.82-0.98; P = .01), as well as hospitalizations for serious adverse events (137.6 vs 153.9 days; RR, 0.89; 95% CI, 0.81-0.98; P = .02). No heterogeneity was observed for the reduction of hospital admissions with semaglutide in selected subgroups, including BMI, age, and sex. Conclusions and Relevance In this prespecified exploratory analysis of the SELECT randomized clinical trial, the trial cohort had a high rate of hospital admissions. Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, extending its benefits beyond CV risk reduction.
Settore MEDS-08/C - Scienza dell'alimentazione e delle tecniche dietetiche applicate
2025
dic-2025
Article (author)
File in questo prodotto:
File Dimensione Formato  
jamacardiology_nicholls_2025_oi_250074_1766159001.00666 (1).pdf

accesso riservato

Tipologia: Publisher's version/PDF
Licenza: Nessuna licenza
Dimensione 417.46 kB
Formato Adobe PDF
417.46 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1214215
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
  • OpenAlex ND
social impact